Dénosumab en routine clinique: précautions à prendre avant, pendant et après [Denosumab in clinical practice : beware before, during and after]

Détails

ID Serval
serval:BIB_F9A725F469AB
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Dénosumab en routine clinique: précautions à prendre avant, pendant et après [Denosumab in clinical practice : beware before, during and after]
Périodique
Revue medicale suisse
Auteur(s)
Lamy O., Gonzalez-Rodriguez E., Stoll D., Aubry-Rozier B.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
19/04/2017
Peer-reviewed
Oui
Volume
13
Numéro
559
Pages
863-866
Langue
français
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Denosumab is a very effective treatment of osteoporosis, easy to use and very well tolerated. Due to some associated risks, a close clinical follow-up is necessary. Before the first injection, it is necessary to correct hypocalcaemia or vitamin D deficiency when present. Calcemia has to be followed in case of renal insufficiency. Injections of denosumab should be done scrupulously every 6 months (± 3 weeks). Discontinuation of denosumab is associated with a severe rebound effect characterized by increased markers of bone remodeling, a rapid decrease of bone density values, and a risk of multiple spontaneous vertebral fractures. The administration of a potent bisphosphonate (zoledronate, alendronate) minimises or avoids this rebound effect.

Mots-clé
Bone Density/drug effects, Bone Density Conservation Agents/administration & dosage, Bone Density Conservation Agents/adverse effects, Bone Remodeling/drug effects, Denosumab/administration & dosage, Denosumab/adverse effects, Diphosphonates/administration & dosage, Diphosphonates/adverse effects, Drug Administration Schedule, Humans, Hypocalcemia/complications, Hypocalcemia/therapy, Osteoporosis/drug therapy, Time Factors, Vitamin D Deficiency/complications, Vitamin D Deficiency/therapy
Pubmed
Création de la notice
01/09/2017 9:16
Dernière modification de la notice
03/02/2020 16:21
Données d'usage